New hope: drug may shield breast cancer patients from dangerous side effect

NCT ID NCT07380646

Recruiting now Disease control Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase II trial tests whether taking leucogen alongside standard ribociclib therapy can prevent severe neutropenia (dangerously low white blood cell counts) in women with early-stage hormone-positive breast cancer. About 94 participants will receive the combination and be monitored for four months. The goal is to see if leucogen can keep white blood cell levels safe, allowing patients to continue their cancer treatment without interruption.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: leucogen (a drug to boost white blood cell production)
What this could lead to: If it works, this could point toward a way to prevent dangerous drops in white blood cells during breast cancer treatment, allowing more patients to stay on their full therapy.
What could go wrong: This is a small, early-phase trial with only 94 participants and no comparison group, so results may not hold up in larger studies. The drug itself may cause side effects like bone pain or allergic reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm hormone receptor-positive breast cancer leukopenia neutropenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER LEUCOGEN NEUTROPENIA (LOW WHITE BLOOD CELL COUNT) RIBOCICLIB

Contacts and locations

Locations

Breast surgery department
RECRUITING

Hangzhou, Zhejiang, 310058, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.